Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 5/20 | 0.64 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | HPGDS | O60760 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | NAMPT | P43490 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MMP13 | P45452 | 1/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14082179 | 0.88 | HPGDS (0.73) | LMNAHPGDSMAPK1MMP13 | |
| SCHEMBL14082168 | 0.86 | MMP13 (0.72) | HTTLMNAHPGDSMAPK1NAMPT | |
| SCHEMBL2984197 | 0.85 | NAMPT (0.72) | HTTLMNAALDH1A1MAPTMAPK1 | |
| SCHEMBL1161997 | 0.85 | NAMPT (0.75) | HTTLMNAALDH1A1MAPTMAPK1 | |
| SCHEMBL27593845 | 0.84 | HPGDS (0.68) | LMNAHPGDSMAPK1MMP13TRPV1 | |
| SCHEMBL14082468 | 0.83 | MMP13 (0.61) | HTTLMNAALDH1A1MAPTMAPK1 | |
| SCHEMBL14082585 | 0.83 | ALDH1A1 (0.69) | HTTLMNAALDH1A1MAPTMAPK1 | |
| SCHEMBL24975530 | 0.82 | HPGDS (0.64) | HTTLMNAHPGDSALDH1A1MAPT | |
| SCHEMBL29801122 | 0.82 | KMT2A (0.66) | HTTLMNAHPGDSALDH1A1MAPT | |
| SCHEMBL24975558 | 0.82 | KMT2A (0.66) | HTTLMNAHPGDSALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | HTT 2699/4885LMNA 2619/4885HPGDS 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.